Verisante Technology Inc. V.VRS

VERISANTE HAS SPARSE COMPETION

[herbacious]

A NALYSTS WERE SMITTEN WITH THE OPPORTUNITY FOR mELAfIND, BASED MOSTLY ON THE SIZE OF ITS POTENTIAL MARKET AND A CLEAR NEED FOR A BETTER TOOL IN THE DIAGNOSIS OF SKIN CANCER.

MelaFind's efficancy is now largely in DOUBT and even the most bullish of analysts seem to be hedging their bets.

Although there are other technologies that have either been recently introduced or are in late stage development  that would directly compete with AURA, the market still remains almost completely up for grabs.

And based on the huge market size and what we expect to be certain competitive advantages (speed versatility for all types of skin cancer, greater accuracy, smaller probe), i believe AURA will be very well received  and expect sales to jump up very fast, following its launch.

do your own due diligence

herb